| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/09/2006 | WO2006024770A2 Phosphole derivatives complexed with metals, and pharmaceutical uses thereof |
| 03/09/2006 | WO2006024699A1 Thioxothiazolidinone compounds for use as pharmaceuticals |
| 03/09/2006 | WO2006024685A1 Combined use of pterostilbene and quercetin for the production of cancer treatment medicaments |
| 03/09/2006 | WO2006024518A1 Combination therapy for immunostimulation |
| 03/09/2006 | WO2006024492A2 Medical implant provided with inhibitors of atp synthesis |
| 03/09/2006 | WO2006024491A1 Methods and compositions for the treatment of cell proliferation |
| 03/09/2006 | WO2006024490A2 Methods and compositions for the treatment of cell proliferation |
| 03/09/2006 | WO2006024489A2 Methods and compositions for the treatment of cell proliferation |
| 03/09/2006 | WO2006024488A2 Medical stent provided with inhibitors of atp synthesis |
| 03/09/2006 | WO2006008470A3 Treatment of tumours |
| 03/09/2006 | WO2006005268A3 Pharmaceutical composition containing polypeptide fragments of serralysins |
| 03/09/2006 | WO2006004703A3 PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY |
| 03/09/2006 | WO2005063820A3 Il-7 fusion proteins |
| 03/09/2006 | WO2005014572A8 Pyrimidylpyrrole derivatives active as kinase inhibitors |
| 03/09/2006 | WO2004106335A8 Harmine derivatives, intermediates used in their preparation, preparation processes and use thereof |
| 03/09/2006 | US20060053498 Full-length human cdnas encoding potentially secreted proteins |
| 03/09/2006 | US20060052594 New corticosteroids |
| 03/09/2006 | US20060052593 diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly ovarian and colon cancers, autoimmune diseases, and related conditions |
| 03/09/2006 | US20060052591 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides |
| 03/09/2006 | US20060052451 Method |
| 03/09/2006 | US20060052433 Compound |
| 03/09/2006 | US20060052419 Use of pyridly amides as inhibitors of angiogenesis |
| 03/09/2006 | US20060052415 N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form |
| 03/09/2006 | US20060052407 crystal of a non-solvate of (3R)-1-butyl-2,5-dioxo-3-[(1R)-1-hydroxy-1-cyclohexylmethyl]-9-[4-(4-carboxyphenyloxy)phenylmethyl]-1,4,9-triazaspiro[5.5]undecane hydrochloride; chemokine antagonist |
| 03/09/2006 | US20060052403 Novel adenine compound and use thereof |
| 03/09/2006 | US20060052398 Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same |
| 03/09/2006 | US20060052393 Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase |
| 03/09/2006 | US20060052381 Solubilized topoisomerase poisons |
| 03/09/2006 | US20060052376 Carboxamides |
| 03/09/2006 | US20060052371 2-(3-cyanophenyl)-4H-1,3-benzothiazin-4-one; cardiovascular, bone or joint diseases, infectious, inflammatory, kidney diseases; safe and good effects of cell death inhibition, Migration Inhibitory Factor (MIF) binding |
| 03/09/2006 | US20060052357 Organometallic anti-tumour agent |
| 03/09/2006 | US20060052329 Regulation of human P2Y1-like G protein-coupled receptor |
| 03/09/2006 | US20060052323 Method to inhibit cell growth using oligonucleotides |
| 03/09/2006 | US20060052319 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes |
| 03/09/2006 | US20060052313 Selective dipeptide inhibitors of kallikrein |
| 03/09/2006 | US20060052297 Method of up-regulating tumor antigen expression using thymalfasin |
| 03/09/2006 | US20060051836 Molecules for disease detection and treatment |
| 03/09/2006 | US20060051753 Methods for determining the response of cells to vegf and uses thereof |
| 03/09/2006 | US20060051423 Chitosan-based transport system |
| 03/09/2006 | US20060051380 Methods and compositions for the targeting of a systemic immune response to specific organs or tissues |
| 03/09/2006 | US20060051357 Tolerance induction with help of a combination of a lfa-1 inhibitor and a costimulation inhibitor and or a mtor inhibitor |
| 03/09/2006 | US20060051354 Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof |
| 03/09/2006 | US20060051352 CEA binding agents and compositions to reverse CEA-mediated tumorigenic effects on human cancer cells, restore sensitivity to drug induced apoptosis and uses thereof |
| 03/09/2006 | US20060051349 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 03/09/2006 | US20060051335 fusing cells: nucleic acid vector comprises a nucleotide sequence encoding a syncytium-inducing polypeptide that is expressible on a eukaryotic cell surface and comprises a sequence of a gibbon ape leukemia virus |
| 03/09/2006 | US20060051325 Isolation and use of solid tumor stem cells |
| 03/09/2006 | US20060051324 Pharmaceutical composition for inducing an immune response in a human or animal |
| 03/09/2006 | US20060051292 Useful to form complexes having an affinity to targets of interest; verotoxin subunit B |
| 03/09/2006 | DE102004040630A1 Kombinationstherapie mit Procain Combination therapy with procaine |
| 03/09/2006 | CA2797666A1 Peptide derivatives of exendin-3 |
| 03/09/2006 | CA2580748A1 Methods for treating cancer |
| 03/09/2006 | CA2578993A1 Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides |
| 03/09/2006 | CA2578955A1 Isoindolin-1-one derivatives |
| 03/09/2006 | CA2578921A1 Intracellular drug delivery improving liposome |
| 03/09/2006 | CA2578630A1 Pyrimidinylimidazoles as tgf-beta inhibitors |
| 03/09/2006 | CA2578628A1 Pyrimidinylpyrazoles as tgf-beta inhibitors |
| 03/09/2006 | CA2578438A1 Pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoro methyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid |
| 03/09/2006 | CA2577947A1 Novel substituted imidazole derivative |
| 03/09/2006 | CA2577928A1 Molecular chaperone function regulator |
| 03/09/2006 | CA2577278A1 Quinazolinone derivatives and their use as b-raf inhibitors |
| 03/09/2006 | CA2577275A1 Quinazolinone derivatives and their use as b-raf inhibitors |
| 03/09/2006 | CA2577222A1 Isoindoline compounds and methods of making and using the same |
| 03/09/2006 | CA2576924A1 Amide derivatives of 7-amino-3-phenyl-dihydropyrimido [4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
| 03/09/2006 | CA2576818A1 Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
| 03/09/2006 | CA2576781A1 Phosphole derivatives complexed with metals, and pharmaceutical uses thereof |
| 03/09/2006 | CA2576721A1 Use of dendrimers to stimulate cell growth |
| 03/08/2006 | EP1632499A2 Gene sequences amplified in tumours and their diagnostic uses |
| 03/08/2006 | EP1632493A1 Dihydropteridine derivatives, methods for their preparation and their use as drugs |
| 03/08/2006 | EP1632489A1 5-(1,1'-Biphenyl)-4-yl-5-(4-(4-aminoacylphenyl)-piperazin)-1-yl-pyrimidine-2,4,6-trione derivatives, as inhibitors of zinc metallondopeptidases, their preparation and use. |
| 03/08/2006 | EP1632488A1 Cyclic tertiary amine compound |
| 03/08/2006 | EP1632484A1 Thiadiazoline derivative |
| 03/08/2006 | EP1632259A2 Anti-angiogene compositions and methods of use |
| 03/08/2006 | EP1632241A1 Preventive and/or remedy for diseases accompanied by tissue destruction |
| 03/08/2006 | EP1632224A1 Spill resistant pharmaceutical compositions |
| 03/08/2006 | EP1631823A2 NOVEL REGULATORY MECHANISMS OF NF-kappaB |
| 03/08/2006 | EP1631665A1 Novel phosphorylated sequences of the phosphatase cdc25b, antibodies for said sequences and use thereof |
| 03/08/2006 | EP1631592A2 Molecules for targeting and releasing therapeutic compounds, and the use thereof |
| 03/08/2006 | EP1631591A2 Connective tissue growth factor antibodies |
| 03/08/2006 | EP1631560A2 C-fms kinase inhibitors |
| 03/08/2006 | EP1631317A2 Use of vegf inhibitors for tumor regression |
| 03/08/2006 | EP1631295A2 Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer |
| 03/08/2006 | EP1631292A1 4-anilino-quinazoline derivatives as antiproliferative agents |
| 03/08/2006 | EP1631278A1 Combination chemotherapy comprising capecitabine and a liposomal platinum complex |
| 03/08/2006 | EP1631271A2 Methods and compositions for delivery of catecholic butanes for treatment of tumors |
| 03/08/2006 | EP1631146A1 Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments |
| 03/08/2006 | EP1482924A4 Cathepsin cysteine protease inhibitors |
| 03/08/2006 | EP1465627B1 DOSING REGIMEN FOR PPAR−GAMMA ACTIVATORS |
| 03/08/2006 | EP1451303A4 Detection of haematopoietic stem cells and progeny and uses thereof |
| 03/08/2006 | EP1448592B1 Steroidal compounds for inhibiting steroid sulphatase |
| 03/08/2006 | EP1446393B1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase |
| 03/08/2006 | EP1438341B1 Antibody stimulating il-1ra production |
| 03/08/2006 | EP1390371B1 Oxazolo-and furopyrimidines and their use in medicaments against tumors |
| 03/08/2006 | EP1385497B1 Prevention or treatment of breast, prostate and/or cervical cancer with n,n-dimethylglycine |
| 03/08/2006 | EP1374880B1 An antineoplastic drug |
| 03/08/2006 | EP1353926B1 Mikanolide derivatives, their preparation and therapeutic uses |
| 03/08/2006 | EP1349853B1 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections |
| 03/08/2006 | EP1347966B1 Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
| 03/08/2006 | EP1343784B1 UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS and pharmaceutical compositions comprising the same. |
| 03/08/2006 | EP1328527B1 Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents |
| 03/08/2006 | EP1326589B1 Nanoparticles |